Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
The Max Foundation and Novartis deepen global cancer care partnerships with a pledge to reach 100,000 patients annually by 2030
The Max Foundation and Novartis pledge to expand global cancer care, targeting 100,000 patients annually by 2030 with systemic, equity-driven partnerships.
Can immune-based doublets push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can immune-based doublets like TECVAYLI and DARZALEX FASPRO push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Eli Lilly commits $6.5bn to new Houston manufacturing site for small molecule APIs
Eli Lilly invests $6.5B in a Houston API facility to scale orforglipron and small molecule drugs, creating 4,600+ jobs and reshaping U.S. pharma supply.
Atai Life Sciences stock jumps 15% after Beckley Psytech trial update deepens investor interest in BPL-003
Atai Life Sciences stock surged 15% after positive BPL-003 trial data with Beckley Psytech. Investors eye Phase 3 momentum and merger milestones.
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competition—see how dosing, dual-agonist design, and payer rules define the next pharma showdown.
Scilex Holding (SCLX) stock jumps after $200m Semnur Bitcoin deal
Scilex swaps $200M in Semnur stock for Bitcoin as SCLX jumps. See why this bold biotech-crypto move could change investor sentiment and treasury models.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
Clinuvel Pharmaceuticals (ASX: CUV) share price gains after EMA approves year-round SCENESSE dosing
Clinuvel Pharmaceuticals (ASX: CUV) gains EMA approval for year-round SCENESSE dosing, boosting patient access, revenues, and investor sentiment.
BillionToOne’s Unity Fetal Risk screen reshapes cystic fibrosis prenatal testing with early therapeutic pathways
BillionToOne’s Unity Fetal Risk Screen delivers 100% sensitivity in cystic fibrosis prenatal detection, unlocking earlier treatment options for families.
MBX Biosciences stock surges 160% after Canvuparatide Phase 2 success in hypoparathyroidism
MBX Biosciences (NASDAQ: MBX) jumps 160% after Canvuparatide Phase 2 success in hypoparathyroidism; see trial data, stock reaction, and Phase 3 outlook.